T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Australia News News

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service
Australia Latest News,Australia Headlines
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 58 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 71%

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service SciReports mahidolpr immunity SARSCoV2 COVID19 coronavirus covid health healthcare

By Neha MathurJan 18 2023Reviewed by Danielle Ellis, B.Sc. In a recent article published in Scientific Reports, researchers performed an observational study among coronavirus disease 2019 patients and their close contacts registered with the Bangkok home health care services in Thailand. They assessed their T-cell and neutralizing antibody responses six months after exposure to severe acute respiratory syndrome coronavirus 2 .

Moreover, close contacts of infected cases developed T-cell immunity against SARS-CoV-2, which kept COVID-19-related death rates in Bangkok low, even among cases treated at home care centers. However, reluctance to receive the vaccine and the advent of new immune-evading SARS-CoV-2 variants hindered meeting the herd immunity threshold.

Study findings During SARS-CoV-2 exposure, COVID-19 patients and their close contact in each family coinhabited the same healthcare home, with an area of approximately 200 m2. The study population comprised 15 families with 11 members in each family, and 58% were females. Over 90% of members were under 60, and 81% had a body mass index of less than 30. In addition, one-fifth of the study participants, 26.5% of the patients and 15.

Conversely, the researchers noted a decrease in T-cell responses against the S antigen increased as vaccine doses, i.e., with the third or fourth booster. Thankfully, studies have demonstrated T-cell responses against the SARS-CoV-2 Omicron variant rapidly reactivated three months after boosting. Vaccine type might have confounded these responses.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

S. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein AS. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein AS. aureus enhances replication of SARS-CoV-2 in vitro through the bacterial iron-regulated surface determinant protein A WesternU SARSCoV2 bacteria virus covid coronavirus covid
Read more »

Overall patterns of SARS-CoV-2 caused by variants of concern among children and adolescentsOverall patterns of SARS-CoV-2 caused by variants of concern among children and adolescentsOverall patterns of SARS-CoV-2 caused by variants of concern among children and adolescents medrxivpreprint UniBasel_en unibern institutpasteur sheffielduni SARSCoV2 covid coronavirus covid variantsofconcern childhealth teenagers
Read more »

Haemorrhage of human foetal cortex associated with SARS-CoV-2 infectionMassimo et al. report the presence of SARS-CoV-2 in first and second trimester foetal brain tissue in association with cortical haemorrhages. The haemorrhages w
Read more »

The 'Great Escape' by SARS-CoV-2 XBB.1The 'Great Escape' by SARS-CoV-2 XBB.1In a recent article published in the Lancet Microbe, researchers in the Netherlands and the United Kingdom quantified the antigenic diversity of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BQ.1.1, BM.1.1.1, and XBB.1, all derivatives of the variant of concern (VOC) Omicron, which emerged in late 2022.
Read more »

Tight transmission bottlenecks may limit the evolution of SARS-CoV-2 variantsTight transmission bottlenecks may limit the evolution of SARS-CoV-2 variantsA new study describes that tight transmission bottlenecks restrict the evolution of SARS-CoV-2 in the transmission chain. SARS-CoV-2 is the causative pathogen of the COVID-19 pandemic.
Read more »

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the USThe efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the USThe efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US JAMA_current WeillCornell DukeU UMNews JohnsHopkins COVID19 coronavirus covid SARSCoV2
Read more »



Render Time: 2025-03-15 23:05:43